Media Release

10 November 2026

Syntara pauses recruitment in SNT-9465 Phase 1b skin scarring study

Syntara Limited (ASX: SNT), a clinical-stage drug development company, today announces that it has paused recruitment of the Phase 1b study of its topical pan-lysyl oxidase inhibitor, SNT-9465, in participants with hypertrophic sternotomy scars, following an internal review of local tolerability findings from the blinded study population.

After receiving reports of mild to moderate skin irritation in some patients, recruitment has now been paused to allow a thorough review of unblinded data from completed and ongoing patients. Subsequent to this review, a decision on recommencing recruitment or discontinuing the study will be taken.

Syntara CEO Gary Phillips said:

"The feedback received from patients and trial sites during the study supported our decision to expand recruitment and open an additional clinical site to meet recruitment timelines. However, the emergence of tolerability issues in this blinded study population requires us to now pause recruitment and analyse the available data before progressing further.

"We will analyse all collected data to maximise the insights gained to inform our assessment of the potential of this therapeutic approach. We sincerely thank the participants, investigators and study teams for their patience while we complete our review which we expect to complete in this current quarter."

** ENDS **

About Syntara

Syntara Limited (ABN: 75 082 811 630) is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.

Lead candidate amsulostat (also known as SNT-5505 and previously as PXS-5505) is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. Amsulostat has been granted Fast Track Designation, having already achieved FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for development in myelofibrosis. Amsulostat has now completed a Phase 2a trial in myelofibrosis in which it was dosed as monotherapy and in combination with a JAK inhibitor. Two Phase 1c/2 studies with amsulostat in patients with a blood cancer called myelodysplastic syndrome have been initiated.

SNT-4728 is being studied in collaboration with Parkinson's UK as a best-in-class SSAO/MAO-B inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson's by reducing neuroinflammation.

Syntara is evaluating the potential of topical pan-LOX inhibition in skin scarring with SNT-9465 in a Phase 1b study in hypertrophic sternotomy scars. Syntara also continues its collaboration with Professor Fiona Wood and the University of Western Australia studying keloid scars.

Other Syntara drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, MASH, pulmonary fibrosis and cardiac fibrosis.

Syntara developed two respiratory products available in world markets (Bronchitol® for cystic fibrosis and Aridol®- a lung function test), which it sold in October 2023.

Syntara is listed on the Australian Securities Exchange, code SNT. The company's management and scientific discovery team are based in Sydney, Australia. www.syntaraTX.com.au.

SOURCE:
Syntara Limited (ASX: SNT),
Sydney, Australia
(ABN: 75 082 811 630)

AUTHORISED FOR RELEASE TO ASX BY:
Syntara Limited Disclosure Committee.

CONTACT:

Syntara investor / media relations:
Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

JOIN THE SYNTARA MAILING LIST HERE